A Study of Oral Vismodegib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Status:
Withdrawn
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, multicenter, double-blind, placebo-controlled, parallel-group study of
vismodegib in patients with IPF. Eligible patients will be randomized in a 2:1 ratio to one
of two treatment arms: vismodegib or placebo. The duration of treatment will be 52 weeks.
Study drug will be administered daily by the oral route. An 8-week safety follow-up period is
included for all patients who receive at least one dose of study drug.